|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.81 - 34.95|
|52 Week Range||28.74 - 35.90|
|Beta (3Y Monthly)||0.47|
|PE Ratio (TTM)||22.68|
|Forward Dividend & Yield||1.07 (3.10%)|
|1y Target Est||38.75|
Moody's Investors Service ("Moody's") has affirmed the Ba3 corporate family rating and senior unsecured rating of Yestar Healthcare Holdings Company Limited ("Yestar"). At the same time, Moody's has changed the outlook on the ratings to negative from stable.
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year. Roche's drug and Bayer/Lilly's Vitrakvi target tumors with rare genetic anomalies called NTRK fusions, irrespective of where in the body the disease started. Vitrakvi, co-developed by Bayer and Lilly's Loxo Oncology, won approval in November, and is priced at $32,800 per month.
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brainRoche’s first FDA-approved tumour-agnostic.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday. The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. Since these NTRK fusions occur in a multitude of tumors, Roche sees potentially broad application for Rozlytrek, in conjunction with diagnostic tests from its Foundation Medicine unit.
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
The buyout is expected to expand Accenture's (ACN) position as one of the leading experience agencies in the rapidly growing Latin American market.
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
Pfizer stock has tumbled, behind pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Recent volatility in the markets has done little to quell recession fears among investors. Now, closely-followed bond billionaire and DoubleLine Capital CEO Jeffrey Gundlach is sounding the alarm. Yahoo Finance's Julia La Roche joined The Final Round to discuss.